Nextage leads one of the 9 consortia awarded with DECIPHER PCP Phase I tender. Throughout Phase I we will produce the final design of DECIPHER platform competing for Phase II (prototype development).
Our consortium scored a 2nd place (overall result), with the highest technical score among all competitors.
About the consortium
The consortium is a partnership between Nextage and Camelot Biomedical Systems, an hi-tech company based in Genoa.
DECIPHER-PCP aims to develop a mobile solution which enables secure cross-border access to existing patient healthcare portals, with a particular focus on patients with diabetes.